Experienced in Heyde Syndrome

Dr. Daniel L. Spitz

Oncology | Hematology
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
Accepting New Patients
Offers Telehealth
Experienced in Heyde Syndrome
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Spitz is an Oncologist and a Hematologist in Lake Worth, Florida. Dr. Spitz is rated as an Experienced provider by MediFind in the treatment of Heyde Syndrome. His top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Sertoli-Leydig Cell Tumor, and Bone Marrow Aspiration. Dr. Spitz is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Wellington Regional Medical Center
Jupiter Medical Center
Good Samaritan Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
4801 S Congress Ave, Suite 400, Lake Worth, FL 33461
Other Locations
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
5130 Linton Blvd, Suite B4, Delray Beach, FL 33484
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1309 N Flagler Dr, Florida Cancer Specialists, West Palm Beach, FL 33401
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
2848 Ctr Pointe Dr, Fl 1, Fort Myers, FL 33916
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
3401 Pga Blvd, Suite 200, Palm Beach Gardens, FL 33410
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1037 S State Rd 7, 303 Florida Cancer Special, Wellington, FL 33414
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
1970 Golf St, Sarasota, FL 34236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

5 Total Publications

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Journal: Gynecologic oncology
Published: May 13, 2024
Similar Doctors
Advanced in Heyde Syndrome
Dr. Angelina S. The
Oncology | Hematology Oncology | Hematology
Advanced in Heyde Syndrome
Dr. Angelina S. The
Oncology | Hematology Oncology | Hematology

Brrh Oncology, LLC

6282 Linton Blvd, 
Delray Beach, FL 
 (12.0 miles away)
561-495-8307
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angelina The is an Oncologist and a Hematologist Oncology provider in Delray Beach, Florida. Dr. The is rated as a Distinguished provider by MediFind in the treatment of Heyde Syndrome. Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Breast Cancer. Dr. The is currently accepting new patients.

Advanced in Heyde Syndrome
Dr. Harold M. Richter
Oncology | Hematology
Advanced in Heyde Syndrome
Dr. Harold M. Richter
Oncology | Hematology
6282 Linton Blvd, 
Delray Beach, FL 
 (12.0 miles away)
561-495-8307
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Harold Richter is an Oncologist and a Hematologist in Delray Beach, Florida. Dr. Richter is rated as a Distinguished provider by MediFind in the treatment of Heyde Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Myelodysplastic Syndrome (MDS), and Anemia. Dr. Richter is currently accepting new patients.

Advanced in Heyde Syndrome
Dr. Liat N. Dagan
Oncology | Hematology | Hematology Oncology
Advanced in Heyde Syndrome
Dr. Liat N. Dagan
Oncology | Hematology | Hematology Oncology

Brrh Oncology, LLC

800 Meadows Rd, 
Boca Raton, FL 
 (17.0 miles away)
561-955-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Liat Dagan is an Oncologist and a Hematologist in Boca Raton, Florida. Dr. Dagan is rated as a Distinguished provider by MediFind in the treatment of Heyde Syndrome. Her top areas of expertise are Anemia, Chronic Lymphocytic Leukemia (CLL), Thrombocytopenia, and Chronic B-Cell Leukemia (CBCL). Dr. Dagan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spitz's expertise for a condition
ConditionClose
    View All 36 Advanced Conditions
    View All 113 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile